JP2022549007A5 - - Google Patents
Info
- Publication number
- JP2022549007A5 JP2022549007A5 JP2022518768A JP2022518768A JP2022549007A5 JP 2022549007 A5 JP2022549007 A5 JP 2022549007A5 JP 2022518768 A JP2022518768 A JP 2022518768A JP 2022518768 A JP2022518768 A JP 2022518768A JP 2022549007 A5 JP2022549007 A5 JP 2022549007A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- immune cells
- expanded
- cbl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905124P | 2019-09-24 | 2019-09-24 | |
| US62/905,124 | 2019-09-24 | ||
| US201962954323P | 2019-12-27 | 2019-12-27 | |
| US62/954,323 | 2019-12-27 | ||
| US202062961596P | 2020-01-15 | 2020-01-15 | |
| US62/961,596 | 2020-01-15 | ||
| US202062978254P | 2020-02-18 | 2020-02-18 | |
| US62/978,254 | 2020-02-18 | ||
| US202063032462P | 2020-05-29 | 2020-05-29 | |
| US63/032,462 | 2020-05-29 | ||
| PCT/US2020/052317 WO2021061853A1 (en) | 2019-09-24 | 2020-09-23 | Cbl inhibitors and compositions for use in adoptive cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549007A JP2022549007A (ja) | 2022-11-22 |
| JP2022549007A5 true JP2022549007A5 (enExample) | 2023-10-03 |
Family
ID=72811970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518710A Pending JP2022549303A (ja) | 2019-09-24 | 2020-09-23 | 免疫細胞を拡大増殖するためのｃｂｌ阻害剤および組成物 |
| JP2022518768A Pending JP2022549007A (ja) | 2019-09-24 | 2020-09-23 | 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518710A Pending JP2022549303A (ja) | 2019-09-24 | 2020-09-23 | 免疫細胞を拡大増殖するためのｃｂｌ阻害剤および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12121540B2 (enExample) |
| EP (2) | EP4034140A1 (enExample) |
| JP (2) | JP2022549303A (enExample) |
| KR (2) | KR20220068227A (enExample) |
| CN (2) | CN114761027A (enExample) |
| AU (2) | AU2020353015A1 (enExample) |
| CA (2) | CA3152293A1 (enExample) |
| IL (2) | IL291577A (enExample) |
| WO (2) | WO2021061870A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3743063A4 (en) * | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| WO2022217123A2 (en) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| AU2022379959A1 (en) * | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| WO2023217067A1 (zh) * | 2022-05-09 | 2023-11-16 | 上海先博生物科技有限公司 | 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用 |
| US20230414598A1 (en) * | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| KR20250050018A (ko) | 2022-08-16 | 2025-04-14 | 그렌마크 파머수티칼스 엘티디. | Cbl-b 저해제로서의 치환된 피리디논 화합물 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| US20070054355A1 (en) | 2003-03-05 | 2007-03-08 | Yuval Reiss | Cbl-b polypeptides, complexes and related methods |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| PL2242749T3 (pl) | 2008-02-05 | 2013-09-30 | Hoffmann La Roche | Nowe pirydynony i pirydazynony |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| EP2566869B1 (en) | 2010-05-07 | 2016-03-02 | Gilead Connecticut, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
| MX2014005282A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de 8-fluoroftalazin-1 (2h) -ona. |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2014040965A1 (en) | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| US9382246B2 (en) | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| MX2017015574A (es) | 2015-06-02 | 2018-08-09 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| AU2016297362B2 (en) | 2015-07-17 | 2020-04-16 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as HDAC inhibitors |
| EP3254701A1 (en) | 2016-06-09 | 2017-12-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections |
| CA3042297A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
-
2020
- 2020-09-23 EP EP20789344.7A patent/EP4034140A1/en active Pending
- 2020-09-23 CA CA3152293A patent/CA3152293A1/en active Pending
- 2020-09-23 WO PCT/US2020/052335 patent/WO2021061870A1/en not_active Ceased
- 2020-09-23 WO PCT/US2020/052317 patent/WO2021061853A1/en not_active Ceased
- 2020-09-23 JP JP2022518710A patent/JP2022549303A/ja active Pending
- 2020-09-23 AU AU2020353015A patent/AU2020353015A1/en not_active Abandoned
- 2020-09-23 AU AU2020352609A patent/AU2020352609A1/en not_active Abandoned
- 2020-09-23 US US17/030,335 patent/US12121540B2/en active Active
- 2020-09-23 EP EP20803324.1A patent/EP4034141A1/en active Pending
- 2020-09-23 KR KR1020227011154A patent/KR20220068227A/ko not_active Ceased
- 2020-09-23 CN CN202080081556.1A patent/CN114761027A/zh active Pending
- 2020-09-23 KR KR1020227011316A patent/KR20220068228A/ko not_active Ceased
- 2020-09-23 CN CN202080081550.4A patent/CN114786687A/zh active Pending
- 2020-09-23 JP JP2022518768A patent/JP2022549007A/ja active Pending
- 2020-09-23 CA CA3152281A patent/CA3152281A1/en active Pending
- 2020-09-23 US US17/030,258 patent/US12594263B2/en active Active
-
2022
- 2022-03-21 IL IL291577A patent/IL291577A/en unknown
- 2022-03-21 IL IL291579A patent/IL291579A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022549007A5 (enExample) | ||
| JP7654702B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するｔ細胞 | |
| KR102878032B1 (ko) | 입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법 | |
| JP7098615B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| Vuckovic et al. | Bone marrow transplantation generates T cell–dependent control of myeloma in mice | |
| CN1981031B (zh) | 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用 | |
| JP2022549303A5 (enExample) | ||
| JP2023093484A (ja) | Ｎｋ細胞の骨髄ホーミングを改善するｐｍ２１粒子 | |
| US9018004B2 (en) | Method of expanding double negative T cells | |
| CN117295515A (zh) | 用于癌症免疫治疗的嵌合抗原受体修饰的粒细胞-巨噬细胞祖细胞 | |
| CN112074280A (zh) | 前列腺癌特异性骨髓浸润淋巴细胞及其用途 | |
| US20210379106A1 (en) | Oxabicycloheptanes for enhancing car t cell function | |
| TWI757785B (zh) | 細胞激素誘導記憶型自然殺手細胞及其方法 | |
| US12415987B2 (en) | Methods and composition for producing and using immune cells and stem cells for cell-based therapies | |
| Takatsuki et al. | Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance | |
| JP5102773B2 (ja) | 幹細胞のホーミングおよび生着を改善する方法 | |
| US11464805B2 (en) | CCR2+ hematopoietic stem cells mediate T cell activation in adoptive cell therapy | |
| EP3228701A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
| JP2023521671A (ja) | Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法 | |
| CN114729314A (zh) | 用于癌症治疗的组合癌症疗法和细胞因子控制疗法 | |
| US12558424B2 (en) | T cells having enhanced anti-tumor activity | |
| US20230127263A1 (en) | Modified t cells and methods of preparing the same | |
| KR20240055044A (ko) | 림프구 집단 및 이를 생산하는 방법 | |
| WO2013076245A1 (en) | Allogeneic immune response control | |
| CN117120596A (zh) | 高效的m-cenk细胞和方法 |